Navigation Links
Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies

BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation's ONCONASE (ranpirnase) has shown potential to act as a potent payload in antibody conjugates for cancer therapy, according to the latest edition of the Handbook of Therapeutic Antibodies.

In a chapter of the text that reviews immunotoxins, Susanna Rybak, Ph.D. summarizes preclinical research indicating that the specificity and potency of ONCONASE improves in a number of tumor models, including non-Hodgkin's lymphoma, when it is conjugated with various antibodies. Dr. Rybak also reviews evidence that implies that ONCONASE may also be effectively targeted to tumors as a conjugate with non-internalizing antibodies, as compared with the internalizing antibodies required by standard plant and bacterial toxins.

"Antibody-targeted ONCONASE is the most potent targeted ribonuclease (RNase) that I have studied," Dr. Rybak said. "While immunotoxins have entered the arsenal of anti-cancer drugs, there have been problems with their clinical use. ONCONASE's excellent performance in preclinical studies makes it a very promising candidate for testing in the clinic."

"It is a great honor to be included in this important industry reference book," added Kuslima Shogen, Alfacell's chairman and chief executive officer. "This work is further evidence of the opportunity that exists for us to build a significant ONCONASE franchise, as a single agent, in combination therapy or as a payload in antibody conjugates. ONCONASE has the potential to be an effective, highly targeted agent for the treatment of various cancers beyond mesothelioma."

For more than 25 years, Dr. Rybak's research has centered on the biology of RNases, antibody engineering and drug targeting. Her laboratory at the National Cancer Institute (NCI) developed the groundwork for RNase-based therapeutics for NHL and breast cancer. Dr. Rybak, who is a member of Alfac
'"/>




Page: 1 2 3 4

Related medicine technology :

1. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
2. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
3. Researchers Identify Intracellular Pathway of Alfacells Onconase
4. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
5. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
6. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
9. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
10. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
11. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:10/6/2008)...IPPENHAM, England, October 7 /PRNewswire-FirstCall... Index: 4565) and Vectura,Group plc ("Vectura"; LS...evaluating the efficacy, safety and tolerability o...uropean Respiratory Society (ERS) in Berlin,Germa...bromide), a novel,inhaled long-acting muscarinic a...
(Date:10/6/2008)... 6 /PRNewswire-USNewswire/ -- "A return to the use...opment is without scientific,justification," accor...rnatives to Laboratory Animals (ATLA). "An Assessm...earch" concludes that vaccine responses in,chimpan...d that claims of,chimpanzees, critical role and im...
(Date:10/6/2008)...video clips feature children, parents discussing c...ETHESDA, Md., Oct. 6 /PRNewswire-USNewswire/ -- Fr...rch in children saves lives and improves their,hea...al Institutes of,Health (NIH), "Children and Clini...es.nhlbi.nih.gov ), offers parents and health,care...
(Date:10/6/2008)...m Phase 3b Studies with Durezol Dosed Prior to Sur...Therapeutics, Inc., a,privately held ophthalmic-fo...hat Durezol(TM) (difluprednate ophthalmic emulsion...ich was approved by the U.S. Food and,Drug Adminis...icosteroid,indicated for the treatment of inflamma...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 1Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 2Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 3Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 1Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 2Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 3Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 5OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 1OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 2OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 3Latest Advances in Infection Prevention and Control to be Presented in Denver CO at Worlds Largest Annual Infection Prevention Conference June 15 19 20866 1
...rimary Endpoint of Improvement in Overall,Survival...rstCall/ --,Allos Therapeutics, Inc. today announc...otal Phase 3 study of Efaproxyn ,(efaproxiral) plu...th brain metastases originating from breast cancer... of demonstrating a,statistically significant impr...
...2007 /PRNewswire-FirstCall/ -- Anadys,Pharmaceutic...to,the discovery, development and commercializatio...s and cancer, announced today that it,has nominate...s an,orally-administered direct antiviral for the ...tion. , "We have identified a small-molecule, non-...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
(Date:10/6/2008)...if., Oct. 6 /PRNewswire/ -- Today, PARI Pharma Gmb...w Technology that uses single,dose ampoules to con...reating a proprietary, unit-dose ampoule that is r...m using eFlow Technology meets an unmet need by,re...he delivery device,simplifying filling procedures...
(Date:10/6/2008)... 6 /PRNewswire/ -- A special supplement of the Oct...delines for low- and,middle-income countries to im... the most common disease among women worldwide., ...ncer Control -,Implementation" developed by the Br...ered system of resource allocation -- based on cou...
(Date:10/6/2008)... OCI is pleased to announce the launch of ... Denver, Colorado (PRWEB) October...eds of its customers and target market, OCI is ple...site at www.oci.com. The site features improved co...ility. , , ,“Human Resource, Benefits and ht...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3Health News:Information Management Solutions Provider OCI Announces Redesign of Corporate Web Site 2Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
... study says that Man's best friend might be able t... sensitive noses, // dogs can smell odors from mal...ng breeds and ages were trained over seven months ...nts with bladder cancer and that from a control gr...
...s moderate consumption of alcohol may cut the rate...rteries.// Researchers evaluated 225 men after the...ry angioplasty (PTCA), a procedure to open blocked...s surgery, a stent opens the artery but may cause ...
...abetes, Crohn's disease, bowel cancer, constipatio...eir medication orally instead of using injections....that is able to deliver // drugs to manage disease...s ulcerative colitis and some infections. The new ...
...my is a common procedure in children , even though... milder symptoms.// A new study suggests there are...and adenoids in children with mild throat infectio...ages 2 to 8, with recurrent throat infections or e...
Other Medicine News:
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance.
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy.
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu
Medicine Products: